The increasingly acrimonious battle between Endurance Specialty and Aspen Insurance – sparked by an unsolicited $3.2 billion bid for Aspen by Endurance – took a new twist late last week when Aspen moved to block the bid through a shareholders’ rights plan, which Endurance described as a “poison pill”.
If you don't have a login or your access has expired, you will need to purchase a subscription to gain access to this article, including all our online content.
For more information on individual annual subscriptions for full paid access and corporate subscription options please contact us.
To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.
For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk